Skip to main content Skip to search Skip to main navigation

PIC/S: Revision of GMP Guide Annex 13 and new Annex 16

The Pharmaceutical Inspection Co-operation Scheme (PIC/S) has revised its PIC/S GMP Guide to Good Manufacturing Practice (GMP) for Medicinal Products to include

  • the revised Annex 13 on the Manufacture of Investigational Medicinal Products and
  • the new Annex 16 on the Certification by the Authorised Person and Batch Release.

What’s new?

PIC/S Annex 13 (Manufacture of Investigational Medicinal Products) has been revised based on EC Regulation No. 536/2014 on Clinical Trials, which finally entered into force on 31 January 2022. Article 63(1) of the regulation necessitated a revision of Annex 13.

PIC/S Annex 16 (Authorised Person and Batch Release) is new to the PIC/S GMP Guide, as PIC/S did not adopt it parallel to the EU GMP Guide back in the year 2016. At that time, PIC/S considered the document to be EU-specific and difficult to transpose for PIC/S purposes. Under the aspect of international harmonisation of GMP standards, PIC/S now adapted EU Annex 16 to its purposes. For example, PIC/S agreed that elements in Annex 16 related to imported medicinal products would be voluntary, dependent on national law.

The Annexes entered into force on 1 February 2022.

The revised GMP Guide (PE 009-16) can be downloaded here.


Source:

PIC/S: News

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Question of the Week | GMP-Verlag

What are the Benefits and Limitations of Passive Temperature-Controlled Containers for Drug Transport?

Here's the answer:
Read more
Outsourced Activities in the GDP Environment Part II: Contractual Agreements

Outsourced Activities in the GDP Environment Part II: Contractual Agreements

When outsourcing GDP activities, there is a need for concrete delimitation of responsibilities between a client and a contractor. Read more about the goals and the contents of a quality agreement in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more
FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

FDA: Adjustment of Nitrosamine Limits for Short-Term Use Medicines

The FDA has updated its recommendations on Acceptable Intake (AI) limits for nitrosamine impurities. Under certain conditions, the Agency now accepts a Less-Than-Lifetime (LTL) adjustment of AI limits for medicinal products that are not intended for lifetime use. This also represents an alignment with the LTL concept of ICH M7(R2).
Read more
Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

Swissmedic: SMS Registration Becomes Prerequisite for GMP Certificates

As of 15 November 2026, active substances must be registered in the EMA's Substance Management Services (SMS) database before Swissmedic can include them in establishment licences and GMP certificates for active substance manufacturers. The new requirement results from modifications to the EudraGMDP database.
Read more
News: EMA

EMA: New Q&As for Biological Medicinal Products

The EMA has added a new section to its Q&As on biological medicinal products addressing medicinal products containing secretomes or extracellular vesicles (EVs) obtained from human or animal cells.
Read more
News: Europe

EU: Council Adopts the Pharmaceutical Package

On 28 September 2026, the Council of the European Union adopted the EU pharmaceutical package, marking another important step in the legislative process for the comprehensive reform of EU pharmaceutical legislation.
Read more
Previous
Next